241 related articles for article (PubMed ID: 21291867)
1. Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma.
Qi W; Cooke LS; Liu X; Rimsza L; Roe DJ; Manziolli A; Persky DO; Miller TP; Mahadevan D
Biochem Pharmacol; 2011 Apr; 81(7):881-90. PubMed ID: 21291867
[TBL] [Abstract][Full Text] [Related]
2. Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma.
Mahadevan D; Stejskal A; Cooke LS; Manziello A; Morales C; Persky DO; Fisher RI; Miller TP; Qi W
Clin Cancer Res; 2012 Apr; 18(8):2210-9. PubMed ID: 22374334
[TBL] [Abstract][Full Text] [Related]
3. AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas.
Qi W; Liu X; Cooke LS; Persky DO; Miller TP; Squires M; Mahadevan D
Int J Cancer; 2012 Jun; 130(12):2997-3005. PubMed ID: 21796626
[TBL] [Abstract][Full Text] [Related]
4. The combination of alisertib, an investigational Aurora kinase A inhibitor, and docetaxel promotes cell death and reduces tumor growth in preclinical cell models of upper gastrointestinal adenocarcinomas.
Sehdev V; Katsha A; Ecsedy J; Zaika A; Belkhiri A; El-Rifai W
Cancer; 2013 Feb; 119(4):904-14. PubMed ID: 22972611
[TBL] [Abstract][Full Text] [Related]
5. A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma.
Görgün G; Calabrese E; Hideshima T; Ecsedy J; Perrone G; Mani M; Ikeda H; Bianchi G; Hu Y; Cirstea D; Santo L; Tai YT; Nahar S; Zheng M; Bandi M; Carrasco RD; Raje N; Munshi N; Richardson P; Anderson KC
Blood; 2010 Jun; 115(25):5202-13. PubMed ID: 20382844
[TBL] [Abstract][Full Text] [Related]
6. Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).
Maris JM; Morton CL; Gorlick R; Kolb EA; Lock R; Carol H; Keir ST; Reynolds CP; Kang MH; Wu J; Smith MA; Houghton PJ
Pediatr Blood Cancer; 2010 Jul; 55(1):26-34. PubMed ID: 20108338
[TBL] [Abstract][Full Text] [Related]
7. Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment.
Qi W; Spier C; Liu X; Agarwal A; Cooke LS; Persky DO; Chen D; Miller TP; Mahadevan D
Leuk Res; 2013 Apr; 37(4):434-9. PubMed ID: 23153524
[TBL] [Abstract][Full Text] [Related]
8. The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo.
Zhou N; Singh K; Mir MC; Parker Y; Lindner D; Dreicer R; Ecsedy JA; Zhang Z; Teh BT; Almasan A; Hansel DE
Clin Cancer Res; 2013 Apr; 19(7):1717-28. PubMed ID: 23403633
[TBL] [Abstract][Full Text] [Related]
9. MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel.
Shimomura T; Hasako S; Nakatsuru Y; Mita T; Ichikawa K; Kodera T; Sakai T; Nambu T; Miyamoto M; Takahashi I; Miki S; Kawanishi N; Ohkubo M; Kotani H; Iwasawa Y
Mol Cancer Ther; 2010 Jan; 9(1):157-66. PubMed ID: 20053775
[TBL] [Abstract][Full Text] [Related]
10. Additive effects of vorinostat and MLN8237 in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines.
Muscal JA; Scorsone KA; Zhang L; Ecsedy JA; Berg SL
Invest New Drugs; 2013 Feb; 31(1):39-45. PubMed ID: 22669335
[TBL] [Abstract][Full Text] [Related]
11. Aurora A selective inhibitor MLN8237 suppresses the growth and survival of HTLV-1-infected T-cells in vitro.
Tomita M; Mori N
Cancer Sci; 2010 May; 101(5):1204-11. PubMed ID: 20180813
[TBL] [Abstract][Full Text] [Related]
12. The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells.
Sehdev V; Peng D; Soutto M; Washington MK; Revetta F; Ecsedy J; Zaika A; Rau TT; Schneider-Stock R; Belkhiri A; El-Rifai W
Mol Cancer Ther; 2012 Mar; 11(3):763-74. PubMed ID: 22302096
[TBL] [Abstract][Full Text] [Related]
13. Translational exposure-efficacy modeling to optimize the dose and schedule of taxanes combined with the investigational Aurora A kinase inhibitor MLN8237 (alisertib).
Huck JJ; Zhang M; Mettetal J; Chakravarty A; Venkatakrishnan K; Zhou X; Kleinfield R; Hyer ML; Kannan K; Shinde V; Dorner A; Manfredi MG; Shyu WC; Ecsedy JA
Mol Cancer Ther; 2014 Sep; 13(9):2170-83. PubMed ID: 24980948
[TBL] [Abstract][Full Text] [Related]
14. Effects of selective inhibitors of Aurora kinases on anaplastic thyroid carcinoma cell lines.
Baldini E; Tuccilli C; Prinzi N; Sorrenti S; Antonelli A; Gnessi L; Morrone S; Moretti C; Bononi M; Arlot-Bonnemains Y; D'Armiento M; Ulisse S
Endocr Relat Cancer; 2014 Oct; 21(5):797-811. PubMed ID: 25074669
[TBL] [Abstract][Full Text] [Related]
15. Alisertib added to rituximab and vincristine is synthetic lethal and potentially curative in mice with aggressive DLBCL co-overexpressing MYC and BCL2.
Mahadevan D; Morales C; Cooke LS; Manziello A; Mount DW; Persky DO; Fisher RI; Miller TP; Qi W
PLoS One; 2014; 9(6):e95184. PubMed ID: 24893165
[TBL] [Abstract][Full Text] [Related]
16. Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism.
Kelly KR; Nawrocki ST; Espitia CM; Zhang M; Yang JJ; Padmanabhan S; Ecsedy J; Giles FJ; Carew JS
Int J Cancer; 2012 Dec; 131(11):2693-703. PubMed ID: 22488249
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer.
Carol H; Boehm I; Reynolds CP; Kang MH; Maris JM; Morton CL; Gorlick R; Kolb EA; Keir ST; Wu J; Wozniak AE; Yang Y; Manfredi M; Ecsedy J; Wang J; Neale G; Houghton PJ; Smith MA; Lock RB
Cancer Chemother Pharmacol; 2011 Nov; 68(5):1291-304. PubMed ID: 21448591
[TBL] [Abstract][Full Text] [Related]
18. The Aurora-A inhibitor MLN8237 affects multiple mitotic processes and induces dose-dependent mitotic abnormalities and aneuploidy.
Asteriti IA; Di Cesare E; De Mattia F; Hilsenstein V; Neumann B; Cundari E; Lavia P; Guarguaglini G
Oncotarget; 2014 Aug; 5(15):6229-42. PubMed ID: 25153724
[TBL] [Abstract][Full Text] [Related]
19. MLN8237 ( alisertib ) and its role in peripheral T-cell lymphoma.
Alrifai D; Pettengell R
Expert Opin Investig Drugs; 2014 Dec; 23(12):1731-6. PubMed ID: 25323772
[TBL] [Abstract][Full Text] [Related]
20. Aurora kinases as targets in drug-resistant neuroblastoma cells.
Michaelis M; Selt F; Rothweiler F; Löschmann N; Nüsse B; Dirks WG; Zehner R; Cinatl J
PLoS One; 2014; 9(9):e108758. PubMed ID: 25268132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]